Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Alona Zer(Rambam Health Care Campus), Frances A. Shepherd(University Health Network), Allan Hackshaw(Cancer Research UK), Siow Ming Lee(University College London Hospitals NHS Foundation Trust), Lesley Seymour(Queen's University), Ming‐Sound Tsao(Kumamoto University), Lei Han(Queen's University), Penelope A. Bradbury(University Health Network), Keyue Ding(Ontario Institute for Cancer Research), Christopher J. O’Callaghan(Queen's University), Glenwood Goss(Ottawa Hospital)
Cited by 55
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k